{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T01:37:28Z","timestamp":1792633048328,"version":"4.5.0"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Life Sciences"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.lfs.2020.118966","type":"journal-article","created":{"date-parts":[[2021,1,19]],"date-time":"2021-01-19T11:12:56Z","timestamp":1611054776000},"page":"118966","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"special_numbering":"C","title":["Beinaglutide shows significantly beneficial effects in diabetes\/obesity-induced nonalcoholic steatohepatitis in ob\/ob mouse model"],"prefix":"10.1016","volume":"270","author":[{"given":"Xiankang","family":"Fang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqiang","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunling","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanshan","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengyu","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiajie","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianhua","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maiyun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yajun","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.lfs.2020.118966_bb0005","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","article-title":"The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"71","author":"Younossi","year":"2019","journal-title":"J. Hepatol."},{"issue":"4","key":"10.1016\/j.lfs.2020.118966_bb0010","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.jhepr.2019.07.002","article-title":"From NASH to diabetes and from diabetes to NASH: mechanisms and treatment options","volume":"1","author":"Gastaldelli","year":"2019","journal-title":"JHEP Rep."},{"issue":"2","key":"10.1016\/j.lfs.2020.118966_bb0015","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.jhep.2017.12.001","article-title":"A critical review of endpoints for non-cirrhotic NASH therapeutic trials","volume":"68","author":"Ratziu","year":"2018","journal-title":"J. Hepatol."},{"issue":"5","key":"10.1016\/j.lfs.2020.118966_bb0020","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1111\/j.1572-0241.2005.41334.x","article-title":"One-year intense nutritional counseling results in histological improvement in patients with non-alcoholic steatohepatitis: a pilot study","volume":"100","author":"Huang","year":"2005","journal-title":"Am. J. Gastroenterol."},{"issue":"12","key":"10.1016\/j.lfs.2020.118966_bb0025","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1038\/nrendo.2012.140","article-title":"GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus","volume":"8","author":"Meier","year":"2012","journal-title":"Nat Rev Endocrinol."},{"issue":"7","key":"10.1016\/j.lfs.2020.118966_bb0030","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1038\/s41574-018-0016-2","article-title":"Glucagon-like peptide 1 in health and disease","volume":"14","author":"Andersen","year":"2018","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.lfs.2020.118966_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2019.154001","article-title":"Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: think out of the box!","volume":"101","author":"Ranjbar","year":"2019","journal-title":"Metabolism"},{"issue":"9","key":"10.1016\/j.lfs.2020.118966_bb0040","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.2337\/diacare.17.9.1039","article-title":"Subcutaneous injection of the incretin hormone glucagon-like peptide 1 abolishes postprandial glycemia in NIDDM","volume":"17","author":"Gutniak","year":"1994","journal-title":"Diabetes Care"},{"issue":"12","key":"10.1016\/j.lfs.2020.118966_bb0045","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1007\/s001250050613","article-title":"Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM","volume":"39","author":"Nauck","year":"1996","journal-title":"Diabetologia"},{"issue":"3","key":"10.1016\/j.lfs.2020.118966_bb0050","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1079\/BJN20031064","article-title":"Prandial subcutaneous injections of glucagon-like peptide-1 cause weight loss in obese human subjects","volume":"91","author":"Naslund","year":"2004","journal-title":"Br. J. Nutr."},{"key":"10.1016\/j.lfs.2020.118966_bb0055","doi-asserted-by":"crossref","unstructured":"Herman GA, Bergman A, Stevens C, Kotey P, Yi B, Zhao P, et al. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. J. Clin. Endocrinol. Metab.. 2006;91(11):4612\u20139. doi: https:\/\/doi.org\/10.1210\/jc.2006-1009.","DOI":"10.1210\/jc.2006-1009"},{"issue":"2 Suppl 1","key":"10.1016\/j.lfs.2020.118966_bb0060","article-title":"Pharmacology of GLP-1 agonists: describing the therapeutic potential to patients","volume":"111","author":"Spellman","year":"2011","journal-title":"J Am Osteopath Assoc."},{"key":"10.1016\/j.lfs.2020.118966_bb0065","doi-asserted-by":"crossref","unstructured":"Gilbert MP, Pratley RE. GLP-1 analogs and DPP-4 inhibitors in type 2 diabetes therapy: review of head-to-head clinical trials. Front Endocrinol (Lausanne). 2020;11:178. doi: https:\/\/doi.org\/10.3389\/fendo.2020.00178.","DOI":"10.3389\/fendo.2020.00178"},{"issue":"6\u20137","key":"10.1016\/j.lfs.2020.118966_bb0070","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1080\/00365521.2017.1293154","article-title":"Bariatric surgery - time to replace with GLP-1?","volume":"52","author":"Webb","year":"2017","journal-title":"Scand. J. Gastroenterol."},{"issue":"Suppl. 1","key":"10.1016\/j.lfs.2020.118966_bb0075","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1038\/ijosup.2016.8","article-title":"Bariatric surgery and obesity: influence on the incretins","volume":"6","author":"Laferrere","year":"2016","journal-title":"Int J Obes Suppl."},{"issue":"3","key":"10.1016\/j.lfs.2020.118966_bb0080","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.amjmed.2008.09.041","article-title":"Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis","volume":"122","author":"Buchwald","year":"2009","journal-title":"Am. J. Med."},{"key":"10.1016\/j.lfs.2020.118966_bb0085","doi-asserted-by":"crossref","unstructured":"Gimeno RE, Briere DA, Seeley RJ. Leveraging the gut to treat metabolic disease. Cell Metab.. 2020;31(4):679\u201398. doi: https:\/\/doi.org\/10.1016\/j.cmet.2020.02.014.","DOI":"10.1016\/j.cmet.2020.02.014"},{"issue":"12","key":"10.1016\/j.lfs.2020.118966_bb0090","doi-asserted-by":"crossref","first-page":"4139","DOI":"10.1210\/en.2017-00564","article-title":"The role of GLP-1 in the metabolic success of bariatric surgery","volume":"158","author":"Hutch","year":"2017","journal-title":"Endocrinology"},{"issue":"4","key":"10.1016\/j.lfs.2020.118966_bb0095","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1002\/osp4.342","article-title":"Beinaglutide showed significant weight-loss benefit and effective glycaemic control for the treatment of type 2 diabetes in a real-world setting: a 3-month, multicentre, observational, retrospective, open-label study","volume":"5","author":"Zhang","year":"2019","journal-title":"Obes. Sci. Pract."},{"issue":"11","key":"10.1016\/j.lfs.2020.118966_bb0100","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1016\/j.molmet.2017.09.001","article-title":"Superior reductions in hepatic steatosis and fibrosis with co-administration of a glucagon-like peptide-1 receptor agonist and obeticholic acid in mice","volume":"6","author":"Jouihan","year":"2017","journal-title":"Mol Metab."},{"issue":"4","key":"10.1016\/j.lfs.2020.118966_bb0105","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.molmet.2015.01.009","article-title":"The LXR inverse agonist SR9238 suppresses fibrosis in a model of non-alcoholic steatohepatitis","volume":"4","author":"Griffett","year":"2015","journal-title":"Mol Metab"},{"issue":"33","key":"10.1016\/j.lfs.2020.118966_bb0110","doi-asserted-by":"crossref","first-page":"4904","DOI":"10.3748\/wjg.v25.i33.4904","article-title":"Towards a standard diet-induced and biopsy-confirmed mouse model of non-alcoholic steatohepatitis: impact of dietary fat source","volume":"25","author":"Boland","year":"2019","journal-title":"World J. Gastroenterol."},{"issue":"6","key":"10.1016\/j.lfs.2020.118966_bb0115","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0157298","article-title":"GPR142 controls tryptophan-induced insulin and Incretin hormone secretion to improve glucose metabolism","volume":"11","author":"Lin","year":"2016","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.lfs.2020.118966_bb0120","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1172\/JCI42497","article-title":"Pancreatic GLP-1 receptor activation is sufficient for incretin control of glucose metabolism in mice","volume":"122","author":"Lamont","year":"2012","journal-title":"J. Clin. Invest."},{"issue":"3","key":"10.1016\/j.lfs.2020.118966_bb0125","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1046\/j.1365-2982.2001.00249.x","article-title":"Gastric emptying: the validity of the paracetamol absorption test adjusted for individual pharmacokinetics","volume":"13","author":"Medhus","year":"2001","journal-title":"Neurogastroenterol. Motil."},{"key":"10.1016\/j.lfs.2020.118966_bb0130","doi-asserted-by":"crossref","unstructured":"Papazyan R, Sun Z, Kim YH, Titchenell PM, Hill DA, Lu W, et al. Physiological suppression of Lipotoxic liver damage by complementary actions of HDAC3 and SCAP\/SREBP. Cell Metab.. 2016;24(6):863\u201374. doi: https:\/\/doi.org\/10.1016\/j.cmet.2016.10.012.","DOI":"10.1016\/j.cmet.2016.10.012"},{"issue":"5","key":"10.1016\/j.lfs.2020.118966_bb0135","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.2337\/diabetes.48.5.1026","article-title":"Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob\/ob, db\/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta)","volume":"48","author":"Young","year":"1999","journal-title":"Diabetes"},{"issue":"6","key":"10.1016\/j.lfs.2020.118966_bb0140","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1053\/j.gastro.2007.03.054","article-title":"Biology of incretins: GLP-1 and GIP","volume":"132","author":"Baggio","year":"2007","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.lfs.2020.118966_bb0145","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.jdiacomp.2014.12.006","article-title":"Measurement of the incretin hormones: glucagon-like peptide-1 and glucose-dependent insulinotropic peptide","volume":"29","author":"Kuhre","year":"2015","journal-title":"J. Diabetes Complicat."},{"issue":"12","key":"10.1016\/j.lfs.2020.118966_bb0150","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1172\/JCI105685","article-title":"Plasma insulin responses to oral and intravenous glucose: studies in normal and diabetic sujbjects","volume":"46","author":"Perley","year":"1967","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.lfs.2020.118966_bb0155","doi-asserted-by":"crossref","unstructured":"Vilsboll T, Agerso H, Krarup T, Holst JJ. Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects. J. Clin. Endocrinol. Metab.. 2003;88(1):220\u20134. doi: https:\/\/doi.org\/10.1210\/jc.2002-021053.","DOI":"10.1210\/jc.2002-021053"},{"issue":"4","key":"10.1016\/j.lfs.2020.118966_bb0160","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1002\/ddr.1195","article-title":"Pharmacokinetic actions of exendin-4 in the rat: comparison with glucagon-like peptide-1","volume":"53","author":"Parkes","year":"2001","journal-title":"Drug Dev. Res."},{"key":"10.1016\/j.lfs.2020.118966_bb0165","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.molmet.2019.09.010","article-title":"Glucagon-like peptide 1 (GLP-1)","volume":"30","author":"Muller","year":"2019","journal-title":"Mol Metab."},{"issue":"472","key":"10.1016\/j.lfs.2020.118966_bb0170","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aat3392","article-title":"Anti-obesity effects of GIPR antagonists alone and in combination with GLP-1R agonists in preclinical models","volume":"10","author":"Killion","year":"2018","journal-title":"Sci. Transl. Med."},{"issue":"6","key":"10.1016\/j.lfs.2020.118966_bb0175","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.133429","article-title":"Semaglutide lowers body weight in rodents via distributed neural pathways","volume":"5","author":"Gabery","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.lfs.2020.118966_bb0180","doi-asserted-by":"crossref","first-page":"8918","DOI":"10.1038\/ncomms9918","article-title":"Autocrine selection of a GLP-1R G-protein biased agonist with potent antidiabetic effects","volume":"6","author":"Zhang","year":"2015","journal-title":"Nat. Commun."},{"issue":"8","key":"10.1016\/j.lfs.2020.118966_bb0185","doi-asserted-by":"crossref","first-page":"3103","DOI":"10.1210\/en.2011-0174","article-title":"Peripheral and central GLP-1 receptor populations mediate the anorectic effects of peripherally administered GLP-1 receptor agonists, liraglutide and exendin-4","volume":"152","author":"Kanoski","year":"2011","journal-title":"Endocrinology"},{"issue":"12","key":"10.1016\/j.lfs.2020.118966_bb0190","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1111\/j.1365-2826.2012.02364.x","article-title":"Vagal afferents mediate early satiation and prevent flavour avoidance learning in response to intraperitoneally infused exendin-4","volume":"24","author":"Labouesse","year":"2012","journal-title":"J. Neuroendocrinol."},{"issue":"1\u20132","key":"10.1016\/j.lfs.2020.118966_bb0195","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1385\/JMN:18:1-2:07","article-title":"Interactions of glucagon-like peptide-1 (GLP-1) with the blood-brain barrier","volume":"18","author":"Kastin","year":"2002","journal-title":"J. Mol. Neurosci."},{"key":"10.1016\/j.lfs.2020.118966_bb0200","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2202-13-33","article-title":"Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis","volume":"13","author":"Hunter","year":"2012","journal-title":"BMC Neurosci."},{"issue":"Supplement 1","key":"10.1016\/j.lfs.2020.118966_bb0205","article-title":"357-OR: efficacy and safety of dulaglutide 3mg and 4.5mg vs. dulaglutide 1.5mg: 52-week results from AWARD-11","volume":"69","author":"FRIAS","year":"2020","journal-title":"Diabetes"},{"issue":"6","key":"10.1016\/j.lfs.2020.118966_bb0210","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1002\/oby.22794","article-title":"Semaglutide 2.4 mg for the treatment of obesity: key elements of the STEP trials 1 to 5","volume":"28","author":"Kushner","year":"2020","journal-title":"Obesity (Silver Spring)"},{"issue":"1","key":"10.1016\/j.lfs.2020.118966_bb0215","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/hep.23276","article-title":"Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis","volume":"51","author":"Promrat","year":"2010","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.lfs.2020.118966_bb0220","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1053\/j.gastro.2015.04.005","article-title":"Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis","volume":"149","author":"Vilar-Gomez","year":"2015","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.lfs.2020.118966_bb0225","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1007\/s10620-014-3380-3","article-title":"Total body weight loss of >\/= 10% is associated with improved hepatic fibrosis in patients with nonalcoholic steatohepatitis","volume":"60","author":"Glass","year":"2015","journal-title":"Dig. Dis. Sci."},{"issue":"9","key":"10.1016\/j.lfs.2020.118966_bb0230","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1111\/j.1478-3231.2011.02462.x","article-title":"Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis","volume":"31","author":"Svegliati-Baroni","year":"2011","journal-title":"Liver Int."},{"issue":"6","key":"10.1016\/j.lfs.2020.118966_bb0235","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.jhep.2010.09.032","article-title":"Glucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase","volume":"54","author":"Ben-Shlomo","year":"2011","journal-title":"J. Hepatol."},{"issue":"1","key":"10.1016\/j.lfs.2020.118966_bb0240","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/hep.21006","article-title":"Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob\/ob mice","volume":"43","author":"Ding","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.lfs.2020.118966_bb0245","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.taap.2018.09.032","article-title":"Exendin-4, a glucagon-like peptide-1 receptor agonist, reduces hepatic steatosis and endoplasmic reticulum stress by inducing nuclear factor erythroid-derived 2-related factor 2 nuclear translocation","volume":"360","author":"Yoo","year":"2018","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.lfs.2020.118966_bb0250","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1146\/annurev.cellbio.22.010305.104638","article-title":"Mitochondrial fusion and fission in mammals","volume":"22","author":"Chan","year":"2006","journal-title":"Annu. Rev. Cell Dev. Biol."},{"key":"10.1016\/j.lfs.2020.118966_bb0255","doi-asserted-by":"crossref","unstructured":"Austin S, St-Pierre J. PGC1alpha and mitochondrial metabolism--emerging concepts and relevance in ageing and neurodegenerative disorders. J. Cell Sci.. 2012;125(Pt 21):4963\u201371. doi: https:\/\/doi.org\/10.1242\/jcs.113662.","DOI":"10.1242\/jcs.113662"},{"issue":"4","key":"10.1016\/j.lfs.2020.118966_bb0260","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.cmet.2007.08.014","article-title":"SIRT1 improves insulin sensitivity under insulin-resistant conditions by repressing PTP1B","volume":"6","author":"Sun","year":"2007","journal-title":"Cell Metab."},{"issue":"11","key":"10.1016\/j.lfs.2020.118966_bb0265","doi-asserted-by":"crossref","first-page":"3637","DOI":"10.2337\/db14-0263","article-title":"SIRT1 mediates the effect of GLP-1 receptor agonist exenatide on ameliorating hepatic steatosis","volume":"63","author":"Xu","year":"2014","journal-title":"Diabetes"},{"issue":"5","key":"10.1016\/j.lfs.2020.118966_bb0270","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/s42255-020-0209-6","article-title":"Resolution of NASH and hepatic fibrosis by the GLP-1R\/GcgR dual-agonist Cotadutide via modulating mitochondrial function and lipogenesis","volume":"2","author":"Boland","year":"2020","journal-title":"Nat Metab"},{"key":"10.1016\/j.lfs.2020.118966_bb0275","doi-asserted-by":"crossref","unstructured":"Tanaka K, Masaki Y, Tanaka M, Miyazaki M, Enjoji M, Nakamuta M, et al. Exenatide improves hepatic steatosis by enhancing lipid use in adipose tissue in nondiabetic rats. World J. Gastroenterol.. 2014;20(10):2653\u201363. doi: https:\/\/doi.org\/10.3748\/wjg.v20.i10.2653.","DOI":"10.3748\/wjg.v20.i10.2653"},{"issue":"1","key":"10.1016\/j.lfs.2020.118966_bb0280","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.bbrc.2017.03.010","article-title":"Exenatide improves liver mitochondrial dysfunction and insulin resistance by reducing oxidative stress in high fat diet-induced obese mice","volume":"486","author":"Wang","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."}],"container-title":["Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320520317264?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320520317264?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T20:43:45Z","timestamp":1758401025000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0024320520317264"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":56,"alternative-id":["S0024320520317264"],"URL":"https:\/\/doi.org\/10.1016\/j.lfs.2020.118966","relation":{},"ISSN":["0024-3205"],"issn-type":[{"value":"0024-3205","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Beinaglutide shows significantly beneficial effects in diabetes\/obesity-induced nonalcoholic steatohepatitis in ob\/ob mouse model","name":"articletitle","label":"Article Title"},{"value":"Life Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lfs.2020.118966","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"118966"}}